Results 101 to 110 of about 125,674 (260)
PLoS ONE, 2014 Our previous study showed that besides mRNAs and microRNAs, there are DNA fragments within extracellular vesicles (EVs). The BCR/ABL hybrid gene, involved in the pathogenesis of chronic myeloid leukemia (CML), could be transferred from K562 EVs to ...
Jin Cai +13 more
semanticscholar +1 more source
eJHaem, Volume 7, Issue 1, February 2026.Abstract Background Immunophenotypically defined mixed‐phenotype acute leukemias (MPAL) are rare and remain a diagnostic and therapeutic dilemma. We aim to explore the clinicopathologic characteristics and oncological outcomes of these entities. Methods A total of 52 patients with immunophenotypically defined MPAL were identified from our pathology ...
Bo Zhang +5 more
wiley +1 more source
OncoTarget, 2014 Resistance to Imatinib mesylate (IM) is an emerging problem for patients with chronic myelogenous leukemia (CML). T315I mutation in the Bcr-Abl is the predominant mechanism of the acquired resistance to IM and second generation tyrosine kinase inhibitors
Xin Chen +15 more
semanticscholar +1 more source
Ischemic Stroke in Hypereosinophilic Syndrome: A Clinicopathologic Study of Two Cases
Neuropathology, Volume 46, Issue 1, February 2026.ABSTRACT Ischemic stroke is a rare complication of hypereosinophilic syndrome (HES). Manifestations of stroke in HES have been described in the radiologic literature; however the pathologic characterization of central nervous system (CNS) involvement in HES is limited.
Karina C. Martin +3 more
wiley +1 more source
BCR-ABL induces the expression of Skp2 through the PI3K pathway to promote p27Kip1 degradation and proliferation of chronic myelogenous leukemia cells [PDF]
, 2005 Chronic myelogenous leukemia (CML) is characterized by the expression of the BCR-ABL tyrosine kinase, which results in increased cell proliferation and inhibition of apoptosis.
Albero, M.P. (M. Pilar) +11 more
core
A rare case of melanosis of the hard palate mucosa in a patient with chronic myeloid leukemia [PDF]
, 2015 Imatinib Mesylate, also known as Gleevec or ST1-571, is a tyrosine-kinase inhibitor used as the gold standard medication for the chronic myeloid leukemia (CML); Imatinib has indeed deeply revolutionized the CML therapy allowing most patients to have a ...
Bosco, Daniela +4 more
core +3 more sources
Therapeutic targeting of chromatin alterations in leukemia and solid tumors
International Journal of Cancer, Volume 158, Issue 2, Page 382-408, 15 January 2026.Abstract Alterations in chromatin conformation and post‐translational modification of histones have become increasingly recognized as critical drivers of cancer development, progression, and therapy resistance. Recent advances in drug development have led to the establishment of several highly selective small molecule inhibitors, several of which are ...
Florian Perner +7 more
wiley +1 more source
Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. [PDF]
, 2008 The clinical success of multitargeted kinase inhibitors has stimulated efforts to identify promiscuous drugs with optimal selectivity profiles. It remains unclear to what extent such drugs can be rationally designed, particularly for combinations of ...
Aizenstein, Brian +9 more
core
Long Non-Coding RNAs: New Players in Hematopoiesis and Leukemia [PDF]
, 2015 Long non-coding RNAs (lncRNAs) are important regulators of gene expression that influence almost every step in the life cycle of genes, from transcription to mRNA splicing, RNA decay, and translation.
Ballarino, Monica +2 more
core +2 more sources